Management of Refractory/Relapsed Acute Leukemia with Heart Limitation by Anthracycline-free Chemotherapy Regimens in Pediatric Patients: New Hypothesis and New Approach

Babak Abdolkarimi*, Soheila Zareifar***♦, Mehran Karimi**, Pouria Salajegheh***

*Department of Pediatric Hematology-Oncology, Lorestan University of Medical Sciences, Khoramabad, Iran
**Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
*** Department of Pediatric Hematology-Oncology, Iran University of Medical Sciences, Tehran, Iran

Abstract

Background: Anthracycline therapy for acute leukemia may be associated with significant morbidity and mortality in children or elderly patients that have a degree of heart failure. Patients with prior anthracycline exposure, those with pre-existing heart disease, or who have received the total anthracycline dose present an increased risk for cardiotoxicity. Therefore, new chemotherapy regimens in these situations would be life saving for leukemia patients. We have conducted a systematic review of possible strategies for rescue regimens without anthracycline in refractory acute leukemia patients.

Methods: We gathered the data from 5 creation databases and relevant website until August 2016. We selected randomized clinical trials or other studies that used anthracycline-free chemotherapy regimens to treat acute refractory leukemia in children and adults. The quality of the studies was evaluated according to the Cochrane risk of the polarization tool. All stages of the review were independently conducted by two authors. We obtained data from 75 main clinical trials.

Results: There were 75 trials included from which 4 were considered to be at low risk for bias. Most trials showed that the improvement did not reach statistical significance.

Conclusion: Evidence existed to support the use of the combination of fludarabine, cytarabine, and filgrastim, ICE-rituximab chemotherapy regimens, or monoclonal antibodies such as tyrosine kinase inhibitors (Sorafenib) useful for acute refractory/relapsed leukemia.These drugs are used as first salvage regimens or clofarabine and cladribine for acute myeloid leukemia in patients for whom combined anthracycline chemotherapy is inappropriate.

Keywords: Acute leukemia, Non-antracycline regimen, Cardiac toxicity, Chemotherapy

♦Corresponding Author:
Soheila Zareifar, MD
Department of Pediatric Hematology / Oncology, Amir Oncology Hospital, Shiraz University of Medical Sciences, Postal code: 7187915998 Shiraz, Iran
Tel: +98 713 6323731
Email: zareifars@sums.ac.i
zareifars@yahoo.com
b.abdolkarimi@yahoo.com

Introduction

Anthracyclines are one of the most effective compounds in chemotherapy. The adverse effect attributed to these drugs is cardiotoxicity that develops into heart failure.[1] With the aim to maintain the cumulative dose in the normal range, miscellaneous prevention processes can be achieved by the pediatric oncologist to decrease the risk of cardiotoxicity. Regular cardiac monitoring and administration of dexrazoxane and/or the use of a liposomal doxorubicin preparation are effective methods prior to the full cumulative dose.[2]

The selection of an effective, new chemotherapy regimen poses a challenge in acute leukemia patients that relapse following a full cumulative dose of anthracyclines or in patients with antracycline induced heart failure. Therefore, it is necessary and challenging to find a successional strategy instead of anthracyclines.

Establishing a balance between a prescribed suboptimal chemotherapy dosage by the oncologist and preventing relapse of acute leukemia is a challenge. Several methods have been used to reduce cardiotoxicity of the initial exposure to anthracyclines to protect myocardial function.[3]

Pediatric oncologists may administer another chemotherapy regimen to leukemia patients with heart disease, which is similar to elderly patients. This appears to be a valuable outcome in pediatric oncology, but this hypothesis should be explored in a sufficient number of clinical trials.

In adults, new regimens administered based on clofarabine, vosaroxin, sorafenib, fludarabine, and cladribine may effectively replace anthracycline-based regimens in pediatric patients that have refractory/relapsed (R/R) leukemia.

Materials and Methods

Search methods

We obtained data from Pubmed, Medline, Embase, Google Scholar, and CINAHL from August 1995 until August 2016, in addition to a search of relevant websites. English language papers were included and we collected expert opinions or information from seminars such as the American Society of Hematology annual meetings, oral presentations, and abstract papers.

Selection criteria

This review included data from free antracycline chemotherapy regimens for acute refractory leukemia that used a controlled study design (with or without randomization). We included studies that evaluated interventions, policies or programs in place for 12 weeks or more.

Inclusion criteria for selected articles consisted of: publication date between 1995 and 2016; article in English peer-reviewed journals; study was done to minimize bias; identification of all relevant studies; and sufficient similarities between the selected studies to make combining them reasonable.

Exclusion criteria consisted of: not published as a full article (conference proceedings excluded); published in a language other than English; the studied population had underlying disorders except for cancer; and systematic review if they were meeting abstracts not subsequently published in peer-reviewed journals, editorials, commentaries, letters, news articles, case reports, or narrative reviews.

Two review authors independently extracted data and assessed the risk of bias for the included studies.

Main results

Clinical questions of this review included the following question. What chemotherapy regimens are appropriate for refractory relapsed acute leukemia patients with antracycline induced cardiac toxicity?

The research team developed a study protocol to address research questions for the pediatric patient population with acute leukemia. The review included additional studies and related studies found for this update based on the following key words:

"Refractory relapsed acute leukemia AND antracycline free chemotherapy regimens" (10/50),

where the first number was the number of located articles. The second was the number of related articles. Next, we found a number of drugs for recurrent refractory acute leukemia that were the basis for chemotherapy-free anthracycline regimens, such as: vosaroxin, cytarabine, fludarabine, clofarabine, cladribine, sorafenib, and the ICE protocol.

"refractory relapsed acute leukemia vosaroxin plus cytarabine" (3/12)

"refractory relapsed acute leukemia AND cytarabine " (30/95)

"refractory relapsed acute leukemia AND fludarabine " (34/66)

"refractory relapsed acute leukemia AND clofarabine " (25/56)

"refractory relapsed acute leukemia AND cladribine " (33/45)

"refractory relapsed acute leukemia AND ICE protocol " (2/10)

"refractory relapsed acute leukemia AND sorafenib " (24/45)

All studies were screened for children aged 0-18 years or weak elderly adult patients. Review articles included 19 studies of "acute leukemia AND anthracycline free chemotherapy regimens" in children and antracycline free chemotherapy regimens, although the observed heterogeneity rate was high (I2=82%).

We observed heterogeneity in both age groups (adult and pediatric) that could not be explained by the status of randomization or the type, duration, or extent of the intervention.

We found strong evidence that supported the beneficial effects of some chemotherapy drugs which could replace anthracyclines such as rescue or salvage plans in acute leukemia in adults. However, because of unexplained heterogeneity and probability of a low bias study, these results should be interpreted with caution. A wide range of program components were used in these studies, although it was impossible to distinguish which of these components had the most contribution to the observed beneficial effects. Our synthesis indicated the following promising policies and strategies. In the final review we selected 13 articles. Their main results are presented in the references.

Results

We included a total of 75 trials; 4 were considered to be at low risk for bias. Most trials showed that the improvement did not reach statistical significance.

Sorafenib-based regimen

Sorafenib tosylate is a synthetic compound that targets growth signaling and angiogenesis. It affects the critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation. Sorafenib blocks the enzyme RAF kinase. In addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade and, as a result, blocks tumor angiogenesis. Sorafenib with low-dose cytarabine in patients with heart failure is used for R/R acute leukemia.[4-7]

Sorafenib, as a FLT3-ITD inhibitor drug, is an effective treatment in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with the FLT3-ITD mutation . Patients should receive subcutaneous administration of cytarabine (10 mg/m^2 bid) on days 1-10 and oral sorafenib tosylate at doses of 200-600 mg/1.73 m^2 bid on days 2-28. Sorafenib tosylate is added to salvage chemotherapy regimens as a targeted therapy. The anti-leukemic effects of sorafenib and azacytidine have been evaluated in FLT3-ITD + cell lines *in vitro*. Sorafenib and azacitidine showed synergistic inhibition of cell proliferation and apoptosis induction. Subsequently, consolidation azacitidine (100 mg/day × 4 days) subcutaneously every four weeks until disease progression or allogeneic Hematopoetic stem cell transplantation was administered. The total dose of 400 mg per cycle was similar to that used for the maintenance of AML. A 4-day decision-making scheme was practical to avoid wasting medicines and to shorten the duration of administration.[8-11]

Vosaroxin-based regimens

Vosaroxin, is a quinolone-derived intercalating

agent. Initial clinical studies have shown that it is well-tolerated in weak patients with R/R acute leukemia. A synergistic effect with cytarabine (Ara-C) must be considered. Vosaroxin is administered at 90 mg/m^2 intravenously on days 1 and 4 in the first cycle, followed by 70 mg/m^2 in subsequent cycles, and cytarabine (1 g/m^2, intravenously on days 1-5).

Vosaroxina has shown reliable results when combined with cytarabine and might be of clinical benefit to some patients with R/R AML. In elderly patients with acute R/R AML, the situation is similar to pediatric patients with heart failure.[12-20]

Clofarabine-based regimen

Clofarabine is a second generation purine nucleoside analog designed to overcome the limitations and incorporate the best qualities of cladribine and fludarabine. Clofarabine enters the cells by passive transport through lipid membranes, as well as the transport of active nucleosides. Unlike cladribine, clofarabine is active in both AML and ALL. Although cladribine was not active in adult leukemia and induced neurotoxicity in this population, clofarabine showed activity in adult leukemia and did not induce the neurotoxicity associated with other nucleoside analogs. One patient with AML who received clofarabine monotherapy remained in complete remission for 43 weeks without therapy. Once inside the cell, clofarabine is phosphorylated to its active triphosphate form by cellular kinases, including deoxycytidine kinase. While fludarabine and cladribine only inhibit ribonucleotide reductase and DNA polymerase, respectively, clofarabine inhibits both enzymes.[22-24]

In some regimens, the efficacy and safety of administration of intravenous clofarabine (40 mg/m^2), cyclophosphamide (440 mg/m^2), and etoposide (100 mg/m^2) for 5 consecutive days in R/R pediatric patients showed encouraging response rates and sustained remission in R/R patients.[25-28]

In addition, daily intravenous clofarabine (20 mg/m^2) administration for 5 days and cytarabine (20 mg subcutaneously) twice daily for 10 days

is an effective regimen. Clofarabine with low dose of alternate cytarabine and decitabine in consolidation phase is effective in newly diagnosed AML patients with heart conditions.

It seems these regimens are an appropriate approach for first treatment in refractory AML in patients who cannot receive anthracycline. The benefits of prolonged consolidation remain unproven. Additional randomized controlled trials are needed to directly compare the efficacy of clofarabine as a single agent and in combination therapy compared with intensive chemotherapy regimens.[30-34]

Fludarabin-based regimen

Fludarabine phosphate is 2-fluoro, a 5'-monophosphate derivative of vidarabine (Ara-A) with improved solubility. The mechanism of cytotoxic action of the compound appears to involve the metabolic conversion of the active triphosphate.[35,36]

Fludarabine has a substantial activity against lymphoid malignancies. The most popular regimen against lymphoid malignancies is the FLAG protocol that includes two fludarabine 30 mg/m^2/day + Ara-C 2 g/m^2/day for days 1-5 and G-CSF (5 mcg/kg/day) from day 0 to recovery of polymorphonuclear cells. Elderly patients with untreated AML are administered FLAG as initial induction chemotherapy at some adult centers. Primary induction with FLAG in elderly AML patients achieves a high remission rate without prohibitive mucosal or cardiac toxicity and may be considered as an alternative to standard anthracycline-based regimens in this setting.

The FLAG regimen is a non-anthracycline based regimen that may serve as an alternative to the standard induction regimens for AML in older adults or those with significant co-morbidities that include preexisting cardiac disease. It is associated with comparable remission rates and acceptable overall survival in older patients. In addition, it may allow some patients with preexisting cardiac disease to proceed to allo-SCT.[43-47]

ICE-rituximab regimen

Rituximab (375 mg/m^2) was administered on days 1 and 3 of each cycle, ifosfamide (3000 mg/m^2) and etoposide (100 mg/m^2) administered on days 3, 4 and 5, and carboplatin (635 mg/m^2) administered only on day 3.[48-50] ICE-rituximab is administered for 1 to 3 cycles depending on the response.

The combination of rituximab and ICE chemotherapy have safe, acceptable toxicity. At the end of the protocol, some patients could possibly proceed to consolidation with high dose therapy and stem cell rescue. This chemotherapeutic regimen, without the use of an anthracycline drug, has an outcome comparable to other regimens for adult acute leukemia. These regimens were well-tolerated by several ranges patients with acute leukemia, including pediatric patients. The ICE protocol combined with rituximab in childhood Burkitt's leukemia in patients with poor prognoses is useful.[51]

Cladribine (2-CdA)-based regimen

Cladribine (2-CdA) is an adenosine deaminase resistant analog of adenosine induce apoptosis of myeloid cells. 2-CdA has activity in R/R myeloid neoplasms such as pediatric AML with a complete response (CR) rate of 47%. Several studies have confirmed the efficacy of single agent 2-CdA or 2-CdA combination regimens in AML. Established CR rates for combination regimens in R/R adults were approximately 50%, while CR rates for ND adults were approximately 70% and showed similar toxicity profiles to previously used regimens. Despite these promising data, many centers have yet to adopt 2-CdA combination regimens for these difficult-to-treat populations.[52-55]

Cladribine with cytarabine (Ara-C) and G-CSF (CLAG regimen), and re-induction therapy were administered in patients with R/R AML. The protocol consisted of 2-CdA (5 mg/m^2 for 2 hours of infusion per day) for 5 consecutive days. A 4-hour infusion of Ara-C (2 g/m^2) for 2 hours was administered after each 2-CdA infusion. G-CSF (300 microgram) was administered 24 hours prior to the first dose of 2-CdA for 6 days.

In patients with CR, the consolidation treatment begins with a treatment that contains 2-CdA.[56-60] The CLAG regimen has shown significant anti-leukemia activity and acceptable toxicity as reinduction treatment in R/R AML patients. This regimen, CLAG-M, is a well-tolerated, highly effective salvage regimen in poor risk R/R AML. In primary refractory disease, CR was 45.5% for CLAG.[61-63]

Conclusion

Development of an experimental regimen in R/R pediatric acute leukemia remains a clinical challenge, especially without anthracyclines. Evidence exists to support the use of FLAG chemotherapy. ICE-rituximab regimens or monoclonal antibodies such as tyrosine kinase inhibitors (Sorafenib) or clofarabine, cladribine are non-anthracycline agents useful for acute R/R leukemia as a first salvage treatment among AML patients that cannot use anthracyclines..

In the absence of a common therapeutic approach, physicians should compare all currently available methods, including chemotherapy-free anthracycline regimens, targeted therapy, and allogeneic HSCT, or a combination of these as a life-saving options for R/R acute leukemia.

Conflict of Interest

No conflict of interest is declared.

References

1. Volkova M, Russell R 3rd. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. *Curr Cardiol Rev*. 2011;7(4):214-20.
2. Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. *Int J Nanomedicine*. 2007;2(4):567-83.
3. Jiji RS, Kramer CM, Salerno M. Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. *J Nucl Cardiol*. 2012;19(2):377-88.
4. Adnane L, Trail PA, Taylor I, Wilhelm SM. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. *Methods Enzymol*. 2006;407:597-612.
5. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie

D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. *Cancer Res*. 2006;66(24):11851-8.

6. Gollob JA, Wilhelm S, Carter C, Kelley SL. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. *Semin Oncol*. 2006;33(4):392-406.

7. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. *Drugs Today (Barc)*. 2005;41(12):773-84.

8. Ramos NR, Mo CC, Karp JE, Hourigan CS. Current approaches in the treatment of relapsed and refractory acute myeloid leukemia. *J Clin Med.* 2015;4(4):665-95.

9. Hu S, Niu H, Inaba H, Orwick S, Rose C, Panetta JC, et al. Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia. *J Natl Cancer Inst.* 2011;103(11):893-905.

10. Ravandi F, Alattar ML, Grunwald MR, Rudek MA, Rajkhowa T, Richie MA, et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. *Blood.* 2013;121(23):4655-62.

11. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells *in vitro* and *in vivo*. *Blood.* 2002 ;99(11):3885-91.

12. Jamieson GC, Fox JA, Poi M, Strickland SA. Molecular and pharmacologic properties of the anticancer quinolone derivative Vosaroxin: A new therapeutic agent for acute myeloid leukemia. *Drugs*. 2016;76(13):1245-55.

13. Nijenhuis CM, Lucas L, Rosing H, Jamieson G, Fox JA, Schellens JH, et al. Quantification of vosaroxin and its metabolites N-desmethylvosaroxin and O-desmethylvosaroxin in human plasma and urine using high-performance liquid chromatography-tandem mass spectrometry. *J Chromatogr B Analyt Technol Biomed Life Sci.* 2016;1027:1-10.

14. Short NJ, Ravandi F. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review. *Expert Rev Hematol.* 2016;9(6):529-34.

15. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, et al. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. *Lancet Oncol.* 2015;16(9):1025-36.

16. Bornhäuser M. Vosaroxin in acute myeloid leukaemia. *Lancet Oncol*. 2015;16(9):1000-1.

17. Hotinski AK, Lewis ID, Ross DM. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia. *Expert Opin Pharmacother.* 2015;16(9):1395-402.

18. Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, et al. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. *Haematologica.* 2015;100(2):231-7.

19. Feldman EJ. Does therapy-related AML have a poor prognosis, independent of the cytogenetic/molecular determinants? *Best Pract Res Clin Haematol.* 2011;24(4):523-6.

20. Freeman C, Keane N, Swords R, Giles F. Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML? *Expert Opin Pharmacother.* 2013;14(10):1417-27.

21. Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, et al. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. *Haematologica.* 2015;100(2):231-7.

22. Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. *Biochem Pharmacol.* 2011;81(2):222-32.

23. Ghanem H, Kantarjian H, Ohanian M, Jabbour E. The role of clofarabine in acute myeloid leukemia. *Leuk Lymphoma.* 2013;54(4):688-98.

24. Majda K, Lubecka K, Kaufman-Szymczyk A, Fabianowska-Majewska K. Clofarabine (2-chloro-2'-fluoro-2'-deoxyarabinosyladenine)--biochemical aspects of anticancer activity. *Acta Pol Pharm.* 2011;68(4):459-66.

25. Valdez BC, Li Y, Murray D, Ji J, Liu Y, Popat U, et al. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators. *Exp Hematol.* 2015;43(6):448-61.

26. Valdez BC, Li Y, Murray D, Champlin RE, Andersson BS. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling. *Biochem Pharmacol.* 2011;81(2):222-32.

27. Song G, Valdez BC, Li Y, Dominguez JR, Corn P, Champlin RE, et al. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan. *Leuk Lymphoma*. 2014;55(7):1625-34.

28. Månsson E, Flordal E, Liliemark J, Spasokoukotska-ja T, Elford H, Lagercrantz S, et al. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance. *Biochem Pharmacol.* 2003;65(2):237-47.

29. Hijiya N, Thomson B, Isakoff MS, Silverman LB,

Steinherz PG, Borowitz MJ, et al . Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. *Blood.* 2011;118(23):6043-9.

30. Miano M, Pistorio A, Putti MC, Dufour C, Messina C, Barisone E, et al. Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients. *Leuk Lymphoma.* 2012;53(9):1693-8.

31. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, et al. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. *Cancer.* 2015;121(14):2375-82.

32. Hijiya N, Gaynon P, Barry E, Silverman L, Thomson B, Chu R, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. *Leukemia.* 2009;23(12):2259-64.

33. Liu AP, Lee V, Li CK, Ha SY, Chiang AK. Refractory acute lymphoblastic leukemia in Chinese children: bridging to stem cell transplantation with clofarabine, cyclophosphamide and etoposide. *Ann Hematol.* 2016;95(3):501-7.

34. Kadia TM, Faderl S, Ravandi F, Jabbour E, Garcia-Manero G, Borthakur G, et al. Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia. *Cancer.* 2015;121(14):2375-82.

35. Chun HG, Leyland-Jones B, Cheson BD. Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. *J Clin Oncol.* 1991;9(1):175-88.

36. Faderl S, Ravandi F, Huang X, Wang X, Jabbour E, Garcia-Manero G, et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. *Cancer.* 2012;118(18):4471-7.

37. Visani G, Tosi P, Zinzani PL, Manfroi S, Ottaviani E, Testoni N, et al. Leukemia. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. *Leukemia.* 1994;8(11):1842-6.

38. Yılmaz Bengoa Ş, Ataseven E, Kızmazoğlu D, Demir Yenigürbüz F, Erdem M, Ören H. FLAG regimen with or without Idarubicin in children with relapsed/refractory acute leukemia: Experience from a Turkish pediatric hematology center. *Turk J Haematol.* 2017;34(1):46-51.

39. Guolo F, Minetto P, Clavio M, Miglino M, Di Grazia C, Ballerini F, et al. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients. *Am J Hematol.* 2016;91(8):755-62.

40. Becker PS, Medeiros BC, Stein AS, Othus M, Appelbaum FR, Forman SJ, et al. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloprolif-erative neoplasm. *Am J Hematol.* 2015;90(4):295-300.

41. Alwan AF, Matti BF, Naji AS, Jawad AM. The efficacy of Fludarabine, high dose Cytosine Arabinoside with Granulocyte colony stimulating factor (FLAG) protocol as salvage therapy for refractory/relapsed acute leukemias in adult Iraqi patients. *Indian J Hematol Blood Transfus.* 2014;30(4):231-5.

42. Bashey A, Liu L, Ihasz A, Medina B, Corringham S, Keese K, et al. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged 60 or older. *Leuk Res.* 2006;30(4):503-6.

43. Cooper TM, Alonzo TA, Gerbing RB, Perentesis JP, Whitlock JA, Taub JW, et al. AAML0523: a report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. *Cancer.* 2014;120(16):2482-9.

44. Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia. *Leukemia.* 2015;29(4):770-5.

45. Sallman DA, Lancet JE. What are the most promising new agents in acute myeloid leukemia? *Curr Opin Hematol.* 2017;24(2):99-107.

46. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood.* 2010;115(3):453-74.

47. Del Principe MI, Buccisano F, Maurillo L, Sconocchia G, Cefalo M, Consalvo MI, et al. Minimal residual disease in acute myeloid leukemia of adults: Determination, prognostic impact and clinical applications. *Mediterr J Hematol Infect Dis.* 2016;8(1):e2016052.

48. Griffin TC, Weitzman S, Weinstein H, Chang M, Cairo M, Hutchison R, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Pediatr Blood Cancer.* 2009;52(2):177-81.

49. Bruserud O, Reikvam H, Kittang AO, Ahmed AB, Tvedt TH, Sjo M, et al. High-dose etoposide in

allogeneic stem cell transplantation. *Cancer Chemother Pharmacol.* 2012;70(6):765-82.

50. Malbora B, Avci Z, Olgac A, Gursel O, Kurekci E, Ozbek N. Successful treatment of ICE-rituximab chemotherapy and subsequent bone marrow transplantation in a patient with early-relapse Burkitt leukemia and inverted duplication of 1q. *J Pediatr Hematol Oncol.* 2012;34(2):e84-5.

51. Colpo A, Hochberg E, Chen YB. Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma. *Oncologist.* 2012;17(1):80-90.

52. Creutzig U, Dworzak M, Zimmermann M, Bourquin JP, Gruhn B, Fleischhack G, et al. Randomised introduction of 2-CDA as intensification during consolidation for children with high-risk AML--results from study AML-BFM 2004. *Klin Padiatr.* 2015;227(3):116-22.

53. Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, et al. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML. *Leuk Res*. 2008;32(12):1830-6.

54. Robak T, Wrzesień-Kuś A, Lech-Marańda E, Kowal M, Dmoszyńska A. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. *Leuk Lymphoma.* 2000;39(1-2):121-9.

55. Creutzig U, Berthold F, Boos J, Fleischhack G, Gadner H, Gnekow A, et al. Improved treatment results in children with AML: Results of study AML-BFM 93. [Article in German] *Klin Padiatr.* 2001;213(4):175-85.

56. Robak T, Wrzesień-Kuś A, Lech-Marańda E, Kowal M, Dmoszyńska A. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia. *Leuk Lymphoma.* 2000;39(1-2):121-9.

57. Uchida T, Hagihara M, Hua J, Inoue M. The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50. *Leuk Res.* 2017;53:35-8.

58. Paubelle E, Ducastelle-Leprêtre S, Labussière-Wallet H, Nicolini FE, Barraco F, Plesa A, et al. Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant? *Ann Hematol*. 2017;96(3):363-71.

59. Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. *Nat Med.* 2017;23(2):250-5.

60. Ding H, Hashem H, Cabral L, Rangarajan H, Abusin G, Lazarus HM, et al. Azacitidine as a bridge to allogeneic hematopoietic cell transplantation in a pediatric patient with Fanconi anemia and acute myeloid leukemia. *Pediatr Transplant*. 2017;21(2).

61. Wrzesień-Kuś A, Robak T, Lech-Marańda E, Wierzbowska A, Dmoszyńska A, Kowal M, et al. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). *Eur J Haematol.* 2003;71(3):155-62.

62. Wawrzyniak E, Wierzbowska A, Kotkowska A, Siemieniuk-Rys M, Robak T, Knopinska-Posluszny W, et al. Different prognosis of acute myeloid leukemia harboring monosomal karyotype with total or partial monosomies determined by FISH: retrospective PALG study. *Leuk Res.* 2013;37(3):293-9.

63. Robak T, Jamroziak K, Gora-Tybor J, Stella-Holowiecka B, Konopka L, Ceglarek B, et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study). *J Clin Oncol.* 2010;28(11):1863-9.